RSPI (RespireRx Pharmaceuticals) Total Equity: $-12.30 Mil (As of Sep. 2023)


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Total Equity?

RespireRx Pharmaceuticals RSPI 12 Total Equity is $-12.30 Mil as of Sep. 2023. GuruFocus rates RSPI with a GF Score™ of 12/100.

RespireRx Pharmaceuticals's total equity for the quarter that ended in Sep. 2023 was $-12.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

RespireRx Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Total Equity Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.73 -7.45 -8.06 -10.01 -11.88

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.59 -11.88 -12.31 -12.14 -12.30
RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

RespireRx Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2022 is calculated as

Total Equity=Total Assets(Q: Dec. 2022 )-Total Liabilities(Q: Dec. 2022 )
=0.023-11.903
=-11.88

RespireRx Pharmaceuticals's Total Equity for the quarter that ended in Sep. 2023 is calculated as

Total Equity=Total Assets(Q: Sep. 2023 )-Total Liabilities(Q: Sep. 2023 )
=0.109-12.405
=-12.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-12.30 Mil mean?
RespireRx Pharmaceuticals (RSPI) has a Total Equity of $-12.30 Mil as of Sep. 2023. The total amount of equity as record on a company's balance sheet. View historical data for RespireRx Pharmaceuticals and its competitors.
Is RespireRx Pharmaceuticals' Total Equity too high?
RespireRx Pharmaceuticals' current Total Equity is $-12.30 Mil. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' Total Equity compare to CNBX and NAVB?
RespireRx Pharmaceuticals' Total Equity of $-12.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current Total Equity is $-12.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current Total Equity of $-12.30 Mil. The current Total Equity is $-12.30 Mil. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current Total Equity is $-12.30 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price